Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
40,054,940
-
Share change
-
-3,202,836
-
Total reported value
-
$121,364,042
-
Put/Call ratio
-
38%
-
Price per share
-
$3.03
-
Number of holders
-
70
-
Value change
-
-$32,306,355
-
Number of buys
-
41
-
Number of sells
-
50
Institutional Holders of KINNATE BIOPHARMA INC - COM (KNTE) as of Q2 2023
As of 30 Jun 2023,
KINNATE BIOPHARMA INC - COM (KNTE) was held by
70 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,054,940 shares.
The largest 10 holders included
Foresite Capital Management IV, LLC, ORBIMED ADVISORS LLC, Foresite Capital Management V, LLC, Nextech Invest Ltd., Vida Ventures Advisors, LLC, Lynx1 Capital Management LP, VIKING GLOBAL INVESTORS LP, CITADEL ADVISORS LLC, VANGUARD GROUP INC, and MILLENNIUM MANAGEMENT LLC.
This page lists
70
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.